Navigation Links
DSM and LibraGen Sign Agreement to Co-Develop Transaminases for Production of Chiral Amines
Date:9/15/2008

iences that contribute to the quality of life. DSM's products and services are used globally in a wide range of markets and applications, supporting a healthier, more sustainable and more enjoyable way of life. End markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrics and electronics, life protection and housing. DSM has annual sales of almost EUR 8.8 billion and employs some 23,000 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information: http://www.dsm.com.

Forward-looking statements

Any forward-looking statements contained in this press release that involve inherent risks and uncertainties are based on current expectations, estimates and projections of the management of DSM and information currently available. The statements involve certain risks and uncertainties that are difficult to predict and therefore DSM does not guarantee that its expectations will be realized. Furthermore, DSM has no obligation to update any statements contained in this press release.

For further information please contact:

DSM Pharmaceutical Products

Guy Tiene

Director, Marketing & Communications

Tel: +1-973-257-8160

guy.tiene@dsm.com

DSM Pharmaceutical Products

Oliver May

Competence Manager Biocatalysis

Tel: +31 (46) 4760551

Oliver.May@DSM.com

LibraGen

Renaud Nalin

Chief Executive Officer

Tel: +33 562 193 290

nalin@libragen.com

LibraGen

Fabrice Lefevre

Chief Scientific Officer

Tel: +33 562 193 297

f.lefevre@libragen.com


'/>"/>
SOURCE DSM Pharmaceutical Products
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
4. Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
5. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
6. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
7. Lilly and Glenmark Pharmaceuticals Announce License Agreement
8. Siemens Medical Solutions Diagnostics Inks Agreement with KreLo Medical Diagnostics to Expand Thyroid Immunoassay Menu
9. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
10. Juvaris BioTherapeutics Announces Cooperative Research and Development Agreement With The Centers for Disease Control and Prevention
11. Beckman Coulter Announces Licensing Agreements for Molecular Tests with National University of Ireland, Galway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) specializes ... investigational drug for cancer, is designed for injection into ... Its oncology focus is on melanoma, breast cancer and ... trials of PV-10 as a therapy for metastatic melanoma, ... dermatitis and psoriasis. This summer, the ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus ... a biopharmaceutical company leading the discovery and ... announced that it has demonstrated human proof-of-concept ... clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated ... of hepatitis C virus infection ("HCV").  Interim ...
(Date:10/20/2014)... California , 20 de octubre de 2014 ... en el campo de la pulmonología intervencional, anunció ... Estudio RENEW, casi 3 meses antes de lo ... de exención de dispositivo de investigación (IDE) aprobada ... para el sistema de espiral de reducción de ...
Breaking Medicine Technology:Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3
... 2 Data presented today,at the Annual Congress ... investigational oral Factor Xa inhibitor DU-176b reduced the ... patients,undergoing elective unilateral hip replacement surgery. There was ... and the,observed bleeding rates were low across the ...
... Stenting Safe and Effective in Patients ... Has Been Open-Heart Surgery, WASHINGTON, Sept. 1 ... patients with very complex coronary,artery disease can safely choose ... open-heart surgery, says The Society for,Cardiovascular Angiography and Interventions ...
Cached Medicine Technology:Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b 2SCAI: SYNTAX Data Show PCI Is a Good Option for Patients With Complex Coronary Artery Disease 2SCAI: SYNTAX Data Show PCI Is a Good Option for Patients With Complex Coronary Artery Disease 3
(Date:10/22/2014)... Shriners Hospitals for Children® and UK ... current location of Shriners Hospitals for Children - Lexington ... the University of Kentucky Albert B. Chandler Hospital. The ... owned and operated by Shriners Hospitals for Children, and ... and their families well into the future. , “The ...
(Date:10/22/2014)... OR (PRWEB) October 22, 2014 During ... California’s fresh water supply runs dangerously low, Southern Oregon’s ... Southern Oregon’s rivers, despite the lowest mountain snow pack ... in late summer and early autumn.* That was the ... of the new book “Hiking Southern Oregon,” during an ...
(Date:10/22/2014)... Although there are only 24 hours in a day, that doesn’t ... finding time within their busy schedules for exercise and fitness. Fortunately, ... to get in shape. Here are five ways you can reach ... Change Up Your Commute , Consider riding a bike or taking ... your daily routine. If you must use your car to get ...
(Date:10/22/2014)... By Steven Reinberg ... -- Infants who quickly add weight and length may be ... study suggests. In adults, certain genes have been linked ... promote proportionate gains in fat and lean muscle, the researchers ... be heavier and taller. By ages 2 and 3, however, ...
(Date:10/22/2014)... Maureen Salamon HealthDay ... A crucial part of conventional in vitro fertilization (IVF) -- ... instead take place in a device inside the vagina, new ... contend that the device, called an INVOcell, might sharply cut ... also make the technology more accessible to those who don,t ...
Breaking Medicine News(10 mins):Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4
... especially common after the death of a spouse , , ... keep up active social lives as they age may ... finds. , Being socially active may increase feelings ... helping maintain memory, researchers say. Social interaction may also ...
... May 29 PartnerRe Ltd.,(NYSE: PRE ) today ... Benchimol is scheduled to present at the Fox,Pitt-Kelton Cochran ... Opportunities for the Insurers... and the Contrast with,Banks." The ... 6, 2008 from 9 a.m. - 2 p.m. local ...
... published a,new report designed to provide critical strategic ... in the market for diagnostics and treatments,in this ... &,Analysis: Alzheimer,s Disease," is based on in-depth interviews ... involved in ongoing,research., "There is some real ...
... New three-year agreement extends alliance members, access to medical product ... ... systems., LOUDON, Tenn., May 29 Adroit ... by Premier,Purchasing Partners, LP. The new agreement centers on Adroit,s leading,Soft-Temp(R) ...
... Help Firms That Already Offer Insurance to Workers, ERIE, ... than 10,000 uninsured adults in Erie County -- many of ... are on a waiting list,to receive health care coverage -- ... them gain access to health insurance., He said small ...
... DR ),is excited to announce the creation ... division and the errors and omissions (E&O),division., ... leadership of senior vice president and national practice,leader, ... combines all,of Darwin,s health care-related professional liability teams ...
Cached Medicine News:Health News:Active Social Life Helps Keep Aging Mind Sharp 2Health News:Active Social Life Helps Keep Aging Mind Sharp 3Health News:PartnerRe Executive Vice President & Chief Financial Officer Albert Benchimol to Present at the FPK CCW Credit Risk Conference in London on June 6, 2008 2Health News:Cardiovascular Meds May Be Beneficial in Alzheimer's Disease, According to MedPredict Report 2Health News:Adroit Medical Systems Awarded Premier Supplier Contract for Temperature Therapy Systems 2Health News:Governor Rendell Says PA ABC Will Help Low-Wage Small Businesses Pay for Employee Health Coverage 2Health News:Governor Rendell Says PA ABC Will Help Low-Wage Small Businesses Pay for Employee Health Coverage 3Health News:Governor Rendell Says PA ABC Will Help Low-Wage Small Businesses Pay for Employee Health Coverage 4Health News:Darwin Announces Creation of New Health Care and Errors and Omissions Divisions 2Health News:Darwin Announces Creation of New Health Care and Errors and Omissions Divisions 3
... Stealthstation Siremobil Iso-C3D C-Arm imaging system interface ... of mobile C-arm imaging. Combining mobility ... software, the cooperative technologies deliver the most ... 3D imaging is the new standard in ...
... The best of digital mobile imaging ... of,anatomical localization software and instrumentation. Now ... capability to:, Easily Add Visualization ... Dose, Accelerate Intraoperative Decision Making, ...
... the most advanced imaging capabilities into the ... it offers many of the same technologies ... value-oriented platform. Asteion provides the subsecond speed ... scanning, while also supporting everyday, high-resolution scanning ...
... the T.L.I.F. SG Instruments are the ... surgery, offering comprehensive and functionally sound instruments.. ... variety of disc removal and disc preparation ... TLIF procedure. Excellent design, a wide range ...
Medicine Products: